Epicardial adipose tissue expression of adiponectin is lower in patients with hypertension

Journal of Human Hypertension

Volumn 22, Issue 12, 2008, Pages 856-863

  Teijeira Fernandez, E ^a   Eiras, S ^a   Grigorian Shamagian, L ^a   Fernandez, A ^a   Adrio, B ^a   Gonzalez Juanatey, J R ^a  

^a Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RNA; TRIACYLGLYCEROL;

AGE; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; EPICARDIUM; FEMALE; HEART FAILURE; HEART SURGERY; HEART VALVE SURGERY; HUMAN; HUMAN TISSUE; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SEX DIFFERENCE; SUBCUTANEOUS FAT;

ADIPONECTIN; AGED; COMORBIDITY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; OBESITY; PERICARDIUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; SUBCUTANEOUS FAT;

EID: 57049128971     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2008.75     Document Type: Article

References (42)

1. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H et al Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003; 108: 2460-2466.
2. Iacobellis G, Pistilli D, Gucciardo M, Leonetti F, Miraldi F, Brancaccio G et al. Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease. Cytokine 2005; 29: 251-255.
3. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 2000; 343: 1139-1147.
4. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentrations of IL-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-1772.
5. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149-2153.
6. Trayhurn P, Beattie JH. Physiological role of adipose tissue: White adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001; 60: 329-339.
7. Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: Anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2005; 2: 536-543.
8. de Vos AM, Prokop M, Roos CJ, Meijs MF, van der Schouw YT, Rutten A et al. Peri-coronary epicardial adipose tissue is related to cardiovascular risk factors and coronary artery calcification in post-menopausal women. Eur Heart J 2008; 29: 777-783.
9. Iacobellis G, Assael F, Ribaudo MC, Zappaterreno A, Alessi G, Di Mario U et al. Epicardial fat from echocardiography: A new method for visceral adipose tissue prediction. Obes Res 2003; 11: 304-310.
10. Iacobellis G, Ribaudo MC, Assael F, Vecci E, Tiberti C, Zappaterreno A et al. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: A new indicator of cardiovascular risk. J Clin Endocrinol Metab 2003; 88: 5163-5168.
11. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y et al. Novel modulator for endothelial adhesion molecules. Adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476.
12. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J et al Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
13. Kishida K, Nagaretani H, Kondo H, Kobayashi H, Tanaka S, Maeda N et al. Disturbed secretion of mutant adiponectin associated with the metabolic syndrome. Biochem Biophys Res Commun 2003; 306: 286-292.
14. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T et al Structure-function studies of the adipocyte-secreted hormone Acrp30/ adiponectin. Implications for the metabolic regulation and bioactivity. J Biol Chem 2003; 278: 9073-9085.
15. Santaniemi M, Kesaniemi YA, Ukkola O. Low plasma adiponectin is an indicator of the metabolic syndrome. Eur J Endocrinol 2006; 155 745-750.
16. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: An adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002; 13: 84-89.
17. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
18. Nakamura Y, Shimada K, Fukuda D, Shimada Y, Ehara S, Hirose M et al Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 2004; 90: 528-533.
19. Wolk R, Berger P, Lennon RJ, Brilakis ES, Davison DE, Somers VK. Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J 2007; 28: 292-298.
20. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737.
21. George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart 2006; 92: 1420-1424.
22. Tsutamoto T, Tanaka T, Sakai H, Ishikawa C, Fujii M, Yamamoto T et al Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 2007; 28: 1723-1730.
23. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004; 43: 1318-1323.
24. Lee HS, Lee M, Joung H. Adiponectin represents an independent risk factor for hypertension in middle aged Korean women. Asia Pac J Clin Nutr 2007; 16: 10-15.
25. Cesari M, Pessina AC, Zanchetta M, De Toni R, Avogaro A, Pedon L et al. Low plasma adiponectin is associated with coronary artery disease but not with hypertension in high-risk nondiabetic patients. J Intern Med 2006; 260: 474-483.
26. Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH et al. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 2007; 49: 1455-1461.
27. Yilmaz MI, Sonmez A, Caglar K, Celik T, Yenicesu M, Eyileten T et al Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology 2007; 12: 147-153.
28. Iglesias MJ, Eiras S, Pineiro R, Lopez-Otero D, Gallego R, Fernandez AL et al. Gender differences in adiponectin and leptin expression in epicardial and subcutaneous adipose tissue. Findings in patients undergoing cardiac surgery. Rev Esp Cardiol 2006; 59: 1252-1260.
29. Liu YM, Lacorte JM, Viguerie N, Poitou C, Pelloux V, Guy-Grand B et al. Adiponectin gene expression in subcutaneous adipose tissue of obese women in response to short-term very low calorie diet and refeeding. J Clin Endocrinol Metab 2003; 88: 5881-5886.
30. Rasouli N, Yao-Borengasser A, Miles LM, Elbein SC, Kern PA. Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am J Physiol Endocrinol Metab 2006; 290: 42-46.
31. Ogawa Y, Kikuchi T, Nagasaki K, Hiura M, Tanaka Y, Uchiyama M. Usefulness of serum adiponectin level as a diagnostic marker of metabolic syndrome in obese Japanese children. Hypertens Res 2005; 28: 51-57.
32. Banegas JR, Segura J, Ruilope LM, Luque M, Garcia-Robles R, Campo C et al. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 2004; 43: 1338-1344.
33. Llisterri Caro JL, Rodriguez Roca GC, Alonso Moreno FJ, Lou Arnal S, Divison Garrote JA, Santos Rodriguez JA et al. Blood pressure control in Spanish hypertensive patients in Primary Health Care Centres. PRESCAP 2002 Study. Med Clin (Barc) 2004; 122: 165-171.
34. Gonzalez-Juanatey JR, Alegria-Ezquerra E, Aznar-Costa J, Bertomeu-Martinez V, Franch-Nadal J, Palma-Gamizf JL. Knowledge and implementation of cardiovascular risk clinical practice guidelines by general practitioners and specialists. Rev Esp Cardiol 2006; 59 801-806.
35. Bakris GL. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med 2001; 161: 2661-2667.
36. Sans S, Paluzie G, Balana L, Puig T, Balaguer-Vintro I. Trends in prevalence, awareness, treatment and control of arterial hypertension between 1986 and 1996: The MONICA-Catalonia study. Med Clin (Barc) 2001; 117: 246-253.
37. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL et al Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815-3819.
38. Nagasawa A, Fukui K, Funahashi T, Maeda N, Shimomura I, Kihara S et al. Effects of soy protein diet on the expression of adipose genes and plasma adiponectin. Horm Metab Res 2002; 34: 635-639.
39. Koh KK, Quon MJ, Han SH, Ahn JY, Jin DK, Kim HS et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005; 45: 1088-1093.
40. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81.
41. Esposito K, Ciotola M, Carleo D, Schisano B, Saccomanno F, Sasso FC et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 2006; 29: 1071-1076.
42. Li W, Tonelli J, Kishore P, Owen R, Goodman E, Scherer PE et al. Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle. Am J Physiol Endocrinol Metab 2007; 292: E1301-E1307.